Vor Biopharma (VOR) News Today $0.70 -0.01 (-1.40%) (As of 10/23/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Vor Biopharma: Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial OfficerSeptember 30, 2024 | finanznachrichten.deVor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial OfficerSeptember 30, 2024 | globenewswire.comXbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)September 27, 2024 | finanznachrichten.deEvercore ISI Keeps Their Buy Rating on Vor Biopharma (VOR)September 8, 2024 | markets.businessinsider.comVor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Buy" by AnalystsShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among analystSeptember 8, 2024 | marketbeat.comVor Biopharma (VOR) Receives a Buy from BarclaysSeptember 6, 2024 | markets.businessinsider.comVor Biopharma’s Promising Clinical Trials and Strategic Developments Merit a Buy RatingSeptember 6, 2024 | markets.businessinsider.comWhat's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?September 6, 2024 | msn.comVor Biopharma's (VOR) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday.September 6, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Friday.September 6, 2024 | marketbeat.comNew Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 6, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Strategic Acquisitions Bolster Buy Rating for Vor BiopharmaSeptember 6, 2024 | markets.businessinsider.comNew Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 5, 2024 | globenewswire.comHere's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash WiselySeptember 5, 2024 | finance.yahoo.comVor Bio to Participate in Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Buy" from AnalystsVor Biopharma Inc. (NYSE:VOR - Get Free Report) has earned an average rating of "Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokeraAugust 14, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Price Target Lowered to $3.00 at BarclaysBarclays dropped their price target on Vor Biopharma from $10.00 to $3.00 and set an "overweight" rating for the company in a research note on Wednesday.August 14, 2024 | marketbeat.comBuy Rating Backed by Clinical and Financial Strengths at Vor BiopharmaAugust 13, 2024 | markets.businessinsider.comOptimistic Outlook on Vor Biopharma’s Pipeline and Financial Stability Drives Buy RatingAugust 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Vor Biopharma (VOR)August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma Amid Anticipated Clinical Trials and Strong Financial FootingAugust 9, 2024 | markets.businessinsider.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024August 9, 2024 | investorplace.comVor Bio Reports Second Quarter 2024 Financial Results and Provides Company UpdateAugust 8, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 2, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 9, 2024 | globenewswire.comVor Biopharma (NYSE:VOR) Shares Down 7.3% Vor Biopharma (NYSE:VOR) Shares Down 7.3%June 27, 2024 | marketbeat.comInsider Selling: Vor Biopharma Inc. (NYSE:VOR) Insider Sells 14,645 Shares of StockJune 5, 2024 | insidertrades.comVor Biopharma Inc. (NYSE:VOR) Insider Eyal C. Attar Sells 14,645 SharesVor Biopharma Inc. (NYSE:VOR - Get Free Report) insider Eyal C. Attar sold 14,645 shares of the business's stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $1.39, for a total value of $20,356.55. Following the transaction, the insider now owns 96,063 shares of the company's stock, valued at approximately $133,527.57. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.June 4, 2024 | marketbeat.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 4, 2024 | globenewswire.comVor Biopharma (NYSE:VOR) Trading 5.9% Higher Vor Biopharma (NYSE:VOR) Shares Up 5.9%June 4, 2024 | marketbeat.comBio-Thera Solutions, Ltd: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UKMay 28, 2024 | finanznachrichten.deBuy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential ExpansionMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vor Biopharma’s Clinical and Financial FortitudeMay 14, 2024 | markets.businessinsider.comVor Biopharma (NYSE:VOR) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $12.00 price objective on shares of Vor Biopharma in a report on Monday.May 13, 2024 | marketbeat.comSilvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market PotentialMay 11, 2024 | markets.businessinsider.comPromising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor BiopharmaMay 10, 2024 | markets.businessinsider.comVor Biopharma (NYSE:VOR) Receives Outperform Rating from WedbushWedbush restated an "outperform" rating and set a $11.00 price objective on shares of Vor Biopharma in a research report on Friday.May 10, 2024 | marketbeat.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024May 9, 2024 | msn.comVor Bio Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 9, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMay 6, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | globenewswire.comVor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of DirectorsMay 2, 2024 | globenewswire.comVor Biopharma (NYSE:VOR) Earns "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Vor Biopharma in a report on Tuesday.April 23, 2024 | marketbeat.comBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialApril 13, 2024 | markets.businessinsider.comVor Bio to Participate in Upcoming Investor ConferencesApril 1, 2024 | globenewswire.comHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn SituationMarch 29, 2024 | finance.yahoo.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessMarch 28, 2024 | investorplace.comStifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)March 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)March 22, 2024 | markets.businessinsider.comVor Biopharma Inc. Expected to Post Q1 2025 Earnings of ($0.24) Per Share (NYSE:VOR)Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities researchers at Wedbush issued their Q1 2025 earnings estimates for Vor Biopharma in a research report issued on Wednesday, March 20th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.24) for the quMarch 22, 2024 | marketbeat.com Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… Click here to see a unique election-year trade VOR Media Mentions By Week VOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.000.41▲Average Medical News Sentiment VOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼01▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DMAC News Today ATOS News Today CADL News Today MOLN News Today CRBU News Today ATYR News Today GALT News Today IPHA News Today GBIO News Today ADVM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VOR) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VOR Stock Alerts